328P Time toxicity (TT) associated with first-line treatment (1L) in patients (pts) with advanced biliary tract cancer (aBTC)
Naohiro Okano(Kyorin University), Mitesh J. Borad(Jacksonville College), Umair Majeed(Mayo Clinic in Florida), M. Nishioka(Kyorin University), L. Rimassa(IRCCS Humanitas Research Hospital), Masato Hayashi(Kanazawa University), Pedro Luiz Serrano Usón(Hospital Israelita Albert Einstein), Mohamad Bassam Sonbol(WinnMed), Daniel H. Ahn(Mayo Clinic Hospital), Tanios Bekaii‐Saab(WinnMed), Anna Virginia Adriana Pirozzi(Mayo Clinic in Arizona), Shuichi Hironaka(Kyorin University), Celine Hoyek(Mayo Clinic Hospital), M. Teixeira(Hospital Israelita Albert Einstein), Christina Wu(WinnMed), Taro Sato(Kyorin University), Chris O’Donnell(Victorian Institute of Forensic Medicine), Oluseyi Abidoye(Mayo Clinic), Isabella Sforzin(Hospital Israelita Albert Einstein), F. Nagashima(Kyorin University)
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423